Shamburg News · 8-K filed Nov 12, 2026, 6:14 AM EST
enGene Therapeutics Reports Preliminary Fiscal 2026 Cash of $245.8 Million and LEGEND Trial Update
ENGN · enGene Therapeutics Inc.
- Earnings
- Reg FD disclosure
- Other event
- Financial statements
- Materiality: high
enGene Therapeutics Inc. announced results from pivotal Cohort 1 of its Phase 2 LEGEND trial of detalimogene and alignment with the FDA on key components of the planned Biologics License Application. The company estimated approximately $245.8 million in cash, cash equivalents and marketable securities as of October 31, 2026, based on preliminary, unaudited results that have not been finalized or audited by KPMG LLP. The company also furnished updated corporate and investor presentations on November 11, 2026.
Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, 8.01, 9.01, accession 0001193125-26-456703.
Written from the filing by Shamburg Markets. Figures are as reported by the company.